Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarcocimab tedromer (KSI-301) vs Aflibercept in RVO (BEACON)
NCT04592419Phase 3Completed
- Sponsor
- Kodiak Sciences
- Start
- Sep 2020
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of tarcocimab tedromer in macular edema (2 arms), sponsored by Kodiak Sciences. Primary endpoints: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to Week 24 in BRVO Participants and Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to Week 24 in All RVO Patients. Started Sep 2020; status: completed.
02
Drugs
tarcocimab tedromer
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT04592419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04592419.